Navigation Links
CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced preliminary results of a phase 2 clinical trial studying CRx-139 (a synergistic combination of 3mg prednisolone and the antidepressant paroxetine) and 3mg prednisolone alone, in patients with rheumatoid arthritis (RA). This trial served two important purposes. One purpose was to determine the effect of 3mg of prednisolone alone (a very low dose) in RA and to contrast this effect with the activity previously reported with CRx-102, a synergistic combination of very low dose prednisolone and dipyridamole. The results with 3mg prednisolone confirm that the anti-inflammatory benefits previously observed in three phase 2a clinical trials with CRx-102 are due to the synergistic activity of CRx-102's components, as opposed to an effect derived from the prednisolone component alone. Another purpose of the trial was to evaluate the activity of CRx-139 vs. prednisolone alone. CRx-139 did not show statistical significance on the primary endpoint of the trial. CRx-139 did show statistical significance on multiple other endpoints, requiring further analysis.

CRx-102 Confirmed as Superior to Prednisolone Alone and Advances on Plan in RA and OA

Comparison of treatment outcomes for CRx-102 (from previously reported results in RA) versus very low dose prednisolone alone (from the study reported here) shows that CRx-102 is superior to the 3mg of prednisolone alone. Importantly, subjects in the two studies had the same demographics and similar baseline disease status, allowing for comparison of study results. The following table summarizes the ACR 20 scores for CRx-102 and low dose prednisolone, respectively, at 6 weeks, the duration of the CRx-102 RA study. -0-

Trial                              Regimen       Patients   Patients

                                                  Achieving  Achieving

       
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
Post Your Comments:
(Date:5/1/2015)... 2015   Heska Corporation (NASDAQ: HSKA ... of advanced veterinary diagnostic and other specialty veterinary products ... will present at the 16th Annual B. Riley & Co. ... The conference will be held May 12-14, 2015 at Lowes ... management will be available during the day on May 13 ...
(Date:5/1/2015)... 1, 2015 Braeburn Pharmaceuticals announced ... therapeutic focus beyond addiction and pain to ... Braeburn has acquired an implantable, six-month formulation ... for treatment of schizophrenia from Endo Pharmaceuticals. ... rights to other potential applications of the ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation (NYSE: ... continued business momentum and long-term growth strategies at a ... New York City . President and Chief Executive ... opportunities the company has to bring forward meaningful innovation ... markets and deliver shareholder value. "We ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... 2011 The oncology market continues to be a ... all the aspects of successfully launching a new oncology ... supporting the oncology therapeutic area are constantly assessing the ... group. Best Practices, LLC, a leader in ...
... MUNDELEIN, Ill., April 19, 2011 Sysmex, a ... information systems technology, announced today an amended distributorship ... which automatically renews for up to four successive ... instruments including the Sysmex pocH-100 i™ , Sysmex ...
Cached Medicine Technology:Oncology Global Strategic Marketing Study Offers Chance for Resource Benchmarks 2Sysmex America Signs Distributorship Agreement With LABSCO 2
(Date:5/2/2015)... As a nonsurgical staple in the ... neck and décolleté, radiofrequency energy is proving to ... the success of vulvovaginal rejuvenation. In a pilot ... ThermiGyn’s Women’s Health Clinical Advisory Board Chairman Red ... temperature controlled radio frequency, specifically that of ThermiVa, ...
(Date:5/1/2015)... Texas (PRWEB) May 02, 2015 IDLife ... Texas, is proud to announce the addition of its ... Widerstrom is a life long athlete, growing up in ... passion after college by becoming a personal trainer and ... been the face of several TV shows highlighting her ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... 01, 2015 TROY Healthcare Solutions is ... Regional User Group (RUG) Conference in Atlanta, GA from ... User Group Conference provides a forum for client-to-client presentations, ... all aspects of electronic medical record operations, as well ... applications. , In addition to sponsoring the event, TROY ...
(Date:5/1/2015)... Ernst & Young (EY) has announced Melanie ... CSO, and Burak Sezen, Co-Founder & CTO of RowdMap, ... Of The Year® 2015 Awards in the Ohio Valley ... global leader in assurance, tax, transaction and advisory services ... top audit companies in the world. The awards program ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... one of the leading publishers in the fields of ... The Endocrine Society to co-publish a new journal, ... Hormonal cancers include two of the most deadly cancer ... addition to these cancers, Hormones & Cancer ...
... , CHICAGO, Aug. 27 For years, it was ... procedures to save teeth compromised by extensive decay, gum disease and ... said times have changed and patients should forego prolonged dental heroics ... , , "There really is no justification ...
... ... at ASHG 2009 Meeting in Honolulu, Hawaii -- October 20-24, 2009, Hawaii Convention Center ... Bethesda, MD (Vocus) August 27, ... in Honolulu, Hawaii to present their latest research findings at the 59th Annual Meeting ...
... ... is trying to identify some of the factors that play into a smoker,s decision to quit. ... Manhasset, NY (Vocus) August 27, 2009 ... you may get an equal number of different answers. Christine Metz, PhD, is a scientist at ...
... shows , THURSDAY, Aug. 27 (HealthDay News) -- Children ... overcome their allergy by drinking increasingly higher doses of ... from Johns Hopkins Children,s Center in Baltimore reported that ... immune systems to tolerate milk and other dairy products ...
... , WEST PALM BEACH, Fla., Aug. ... is has added a new module designed to help physicians manage ... service and employee motivation are two of the most important yet ... Beer. , , Leading this new module is ...
Cached Medicine News:Health News:Springer signs publishing agreement with the Endocrine Society 2Health News:Why Save Bad Teeth? Dental 'Heroics' Unnecessary and Failure Prone 2Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 2Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 3Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 4Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 5Health News:Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response 2Health News:Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response 3Health News:Milk Allergy Symptoms May Ease With Exposure 2
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: